Statins in the 21st century: end of the simple story?

Bibliography

• VAUGHAN CJ, GOTTO AM JR, BASS ON CT: The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol (2000) 35:1–10.
   PubMed Web of Science ®Google Scholar
• Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel JJ). JAMA (1993) 269:3015–3023.
   PubMed Web of Science ®Google Scholar
• ANSELL BJ, WATSON KE, FOGELMAN AM: An evidence-based assessment of the NCEP Adult Treatment Panel II Guidelines. National Cholesterol Education Program. JAMA (1999) 282:2051–2057.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• ••Landmark trial showing simvastatinlowered mortality in patients with coronary heart disease and high cholesterol.
   Google Scholar
• PEDERSEN TR, KJEKSHUS J, PYORALA K et al.: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study(4S). Am. J. Cardiol (1998) 81:333–335.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, ALEXANDER CM, COOK TJ et al: Reduced coronary events in simvastatin-treated patient with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. (1999) 159:2661–2667.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR, WILHELMSEN L, FAERGEMAN 0 et al: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol (2000) 86:257–262.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE L et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• •Landmark trial showing pravastatin was of benefit in patients with coronary artery disease and average cholesterol levels.
   Google Scholar
• GOLDBERG RB, MELLIES MJ, SACKS FM etal.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels; Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation (1998) 98:2513–2519.
   Google Scholar
• PLEHN JF, DAVID BR, SACKS FM: Reduction of stroke incidence with myocardial infarction after pravastatin; The Cholesterol and Recurrent Events (CARE) Study. Circulation (1999) 99:216–223.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 98:839–844.
   Google Scholar
• •Study linking beneficial effect of a statin to an anti-inflammatory effect.
   Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Ergd. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• MACMAHON S, SHARP N, GAMBLE G et al.: Effects of lowering average or below-average cholesterol on the progression of carotid atherosclerosis; Results of the LIPID atherosclerosis substudy. Circulation (1998) 97:1784–1790.
   PubMed Web of Science ®Google Scholar
• WHITE HD, SIMES RJ, ANDERSON NE et al.: Pravastatin therapy and the risk of stroke. N Engl. J. Med. (2000) 343:317–326.
   PubMed Web of Science ®Google Scholar
• TONKIN AM, COLQUHOUN D, EMBERSON J et al: Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet (2000) 356: 1871-1875.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• ••First study demonstrating primaryprevention of cardiovascular disease with statins.
   Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA (1998) 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• •Trial that demonstrated primary prevention in generally health subjects.
   Google Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282:2340–2346.
   PubMed Web of Science ®Google Scholar
• BLAUW GJ, LAGAAY AM, SMELT AH, WESTENDORP: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke (1997) 28:946–950.
   Google Scholar
• CROUSE JR, BYINGTON R1 HOEN HM, FURBERG CD: Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med. (1997) 157:1305–1310.
   PubMed Web of Science ®Google Scholar
• BROWN G, ALBERS JJ, FISHER LD et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl. J. Med. (1990) 323:1289–1298.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. (1993) 119:969–976.
   Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P etal.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
   Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P etal.: Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation (1995) 92:2404–2410.
   Google Scholar
• WATERS D, LESPERANCE J, GLADSTONE P et al.: Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation (1996) 94:614–621.
   Google Scholar
• THE MAAS TRIAL INVESTIGATORS: Effect of simvastatin on coronary atheroma: the Muticentre Anti-Atheroma Study (MAAS). Lancet (1994) 344:633–638.
   PubMed Web of Science ®Google Scholar
• PITT B, MANCINI GB, ELLIS SG etal.:Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cordial (1995) 26:1133–1139.
   Google Scholar
• JUKEMA JW. BRUSCHKE AV, VAN BOVEN JH et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symtomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528–2540.
   Google Scholar
• BESTEHORN HP, RENSING UF, ROSKAMM H et al.: The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur. Heart. J. (1997) 18:226–234.
   Google Scholar
• HERD JA, BALLANTYN CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cordial (1997) 80:278–286.
   PubMed Web of Science ®Google Scholar
• THE POST CORONARY ARTERY BYPASS GRAFT TRIAL INVESTIGATORS: The effect of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl. J. Med. (1997) 336:153–162.
   PubMed Web of Science ®Google Scholar
• CAMPEAU L, HUNNINGHAKE DB, KNATTERUD GL: Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary bypass graft clinical trial. Post CABG Trial Investigators. Circulation (1999) 99:3241–3247.
   Google Scholar
• KNATTERUD GL, ROSENBERG Y, CAMPEAU L etal.: Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation (2000) 102:157–165.
   Google Scholar
• TEO la, BURTON JR, BULLER CE et al.: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril coronary atherosclerosis trial. Circulation (2000) 102:1748–1754.
   PubMed Web of Science ®Google Scholar
• SAHNI R, MANIET AR, VOCI G, BANKA VS: Prevention of restenosis by lovastatin after successful angioplasty. Am. Heart. J. (1991) 12:1600–1608.
   Web of Science ®Google Scholar
• WEINTRAUB WS, BOCCUZZI SJ, KLEIN JL: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl. J. Med. (1994) 33:1331–1337.
   Google Scholar
• •Trial showing that lovastatin does not prevent restenosis.
   Google Scholar
• KLEEMANN A, ECKERT S, VON ECKARDSTEIN A etal.: Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial. Eur. Heart. J. (1999) 20:1393–1406.
   Google Scholar
• BERTRAND ME, MCFADDEN EP, FRUCHART JC et al.: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J. Am. Coll. Cordial (1997) 30:863–869.
   Google Scholar
• SERRUYS PW, FOLEY DP, JACKSON G etal.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. (1999) 21:58–69.
   Google Scholar
• EGASHIRA K, HIROOKA Y, KAI H et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hyercholesterolemia. Circulation (1994) 89:2519–2524.
   PubMed Web of Science ®Google Scholar
• TREASURE CB, KLEIN JL, WEINTRAUB WS et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl. I Med. (1995) 332:481–487.
   PubMed Web of Science ®Google Scholar
• HAMASAKI S, HIGANO ST, SUWAIDI JA et al: Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly disease coronary arteries. Arterioscler. Thromb. Vase. Biol. (2000) 20:737–743.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, TARDIFF JC, CERNACEK P,THEROUX P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation (1999) 99:3227–3233.
   PubMed Web of Science ®Google Scholar
• HOUGHTON JL, PEARSON TA, REED RG et al.: Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms. Chest (2000) 118:757–760.
   Google Scholar
• TSUNEKAWA T, HAYASHI T, KANO H: Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation (2001) 104:376–379
   PubMed Web of Science ®Google Scholar
• JENKINS GH, GRIEVE LA, UACOUB MH, SINGER DR: Effect of simvastatin on ejection fraction in cardiac transplant recipients. Am. J Cardiol. (1996) 78:1453–1456.
   PubMed Web of Science ®Google Scholar
• SU SF, HSIAO CL, CHU CW, LEE BC, LEE TM: Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol. (2000) 86:514–518.
   PubMed Web of Science ®Google Scholar
• JAY RH, RAMPLING MW, BETTERIDGE DJ: Abnormalities of blood rheology in familial hypercholesterolemia: effect of treatment. Atherosclerosis (1990) 85:249–256.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI AS, LUMBPJ, SEMRAYK,CROOK MA: Effect of atorvastatin on plasma fibrinogen. Lancet (1998) 351:569–570.
   PubMed Web of Science ®Google Scholar
• HOCHGRAF E, LEVY Y, AVIRAM M, BROOK JG, CONGAN H: Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism (1994) 43:11–17.
   PubMed Web of Science ®Google Scholar
• TSUDA Y, SATOH K, KITADAI M, TAKAHASHI T, IZUMI Y, HOSOMI N: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis (1996) 122:225–233.
   PubMed Web of Science ®Google Scholar
• LACOSTE L, LAM JY, HUNG J, LETCHACOVSKI G, SOLYMOSS CB, WATERS D: Hyperlipidemia and coronary disease. Correction of increased thrombogenic potential with cholesterol reduction. Circulation (1995) 92:172–177.
   Google Scholar
• DANGAS G, SMITH DA, UNGER AH et al.: Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost. (2000) 83:688–692.
   PubMed Web of Science ®Google Scholar
• SZCZEKLIK A, MUSIAL J, UNDAS A et al: Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. I Am. Coll Cardiol. (1999) 33:1286–1293.
   PubMed Web of Science ®Google Scholar
• RAUCH U, OSENDE JI, CHESEBRO JH et al.: Statins and cardiovascular disease: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis (2000) 153:181–189.
   PubMed Web of Science ®Google Scholar
• PUCCETTI L, BRUNI E DI RENZO M et al: Hypercoagulable state in hypercholerolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin. Eur. Rev Med. Pharmacol ScL (1999) 3:197–204.
   PubMedGoogle Scholar
• DUJOVNE CA, HARRIS WS, ALTMAN R, OVERHISER RW, BLACK DM: Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am. J Cardiol. (2000) 85:350–353.
   PubMed Web of Science ®Google Scholar
• HOLSCHERMANN H, HILGENDORFF A, KEMKES-MATTHES B etal.: Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation (2000) 69:1830–1836.
   Google Scholar
• TOMAS M, SENTI M, GARCIA-FARIA et al: Effect of simvastatin therapy on paroxonase activity and related lipoproteins in familial hypercholesterolemic patients. Atter/ostler. Th1-0171b. V3SC. Biol. (2000) 20:2113–2119.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKEN CH: Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl. I Med. (1997) 336:973–979.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation (1998) 97:425–428.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, GLYNN RJ, HEMMEKENS CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation (1998) 97:2007–2011.
   PubMed Web of Science ®Google Scholar
• KULLER LH, TRACY RP, SHATEN J, MEILAH EN. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am. Epidemiol. (1996) 144:537–547.
   PubMed Web of Science ®Google Scholar
• THOMPSON SG, KIENAST J, PYKE SDM, HAVERKATE F, VAN DE LOO JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Erigl. Med. (1995) 332:635–641.
   PubMed Web of Science ®Google Scholar
• HAVERKATE F, THOMPSON SG, PYKE SDM, HAVERKATE F, VAN DE LOCO JCW: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet (1997) 349:462–466.
   PubMed Web of Science ®Google Scholar
• LIUZZO G, BIASCUCCI LM, GALLIMORE JR et al: The prognostic value of C-reactive protein and serum amyloid protein in severe unstable angina. N Eng]. J. Med. (1994) 331:417–424.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA,SACKS F, BRAUNWALD E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100:230–235.
   Google Scholar
• ALBERT MA, STAGGERS J, CHEW P, RIDKER PM: The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design. Am. Heart 1. (2001) 141:893–898.
   PubMed Web of Science ®Google Scholar
• HORNE BD, MUHLESTEIN JB, CARLQUIST JF et al: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. I Am. Coll Cardiol. (2000) 36:1774–1780.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, CLEARFIELD Metal.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Erigl. J Med. (2001) 344:1959–1965.
   Google Scholar
• MURPHY RT, FOLEY JB, MULVIHILL N, CREAN P, WALSH MJ: Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am. I Cardiol (2001) 87:446–448.
   PubMed Web of Science ®Google Scholar
• CARLOS TM, HARLAN JM: Leukocyte-Endothelial adhesion molecules. Blood (1994) 84:2068–2101.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-I by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687–692.
   PubMed Web of Science ®Google Scholar
• SPOSITO AC, MANSUR AP COELHO OR, NICOLAU JC, RAMIREZ JA: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. j. Cardiol (1999) 83:1497–1499.
   PubMed Web of Science ®Google Scholar